Although impact investing remains in its nascency in Asia, UBS Wealth Management has raised a chunky US$471 million – 60% of which came from its Hong Kong and Singapore bases – for the final closing of its impacting investing fund dedicated to cancer research. The UBS Oncology Impact fund, where investments are made to accelerate the development of new cancer…
To access this content, please click back to the home screen, then click “Menu” (bars in top left bars) and then “Login”.
To enquire for a free trial, please start here.
Need more help? Click here or email [email protected].
To enquire for a free trial, please start here.
Need more help? Click here or email [email protected].
Subscriber Only Content
This article is available on a corporate subscription with Asian Private Banker. Please login or subscribe to view this content.
Need help? Please see our FAQ Guide or email [email protected]
Have a confidential tip? Get in touch [email protected]
